Product Description
AXS-02is an oral, non-opioid, potentially first-in-class pain therapeutic being developed byAxsomefor the treatment of chronic pain caused by CRPS.
Mechanisms of Action: Bone Resorption Inhibitor, Mevalonate Pathway Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Axsome
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteoarthritis, Knee|Complex Regional Pain Syndromes|Reflex Sympathetic Dystrophy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02746068 |
COAST-1 | P3 |
Unknown status |
Osteoarthritis, Knee |
2020-12-01 |
2021-01-06 |
Primary Endpoints|Treatments|Trial Status |
|
NCT02504008 |
CREATE-1 | P3 |
Unknown status |
Reflex Sympathetic Dystrophy|Complex Regional Pain Syndromes |
2019-01-01 |
22% |
2025-02-07 |
Primary Endpoints |
2015-001527-22 |
CREATEÂ1 Study: CRPS Treatment Evaluation 1 Study | P3 |
Completed |
Complex Regional Pain Syndromes |
2018-11-02 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/09/2020 |
News Article |
Worldwide Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com |
|
04/07/2020 |
News Article |
Insights into the Global Chronic Lower Back Pain Market (2017 to 2030) - Organize Sales and Marketing Efforts by Identifying the Best Opportunities |
|
09/12/2019 |
News Article |
Chronic Lower Back Pain (CLBP) Market - Global Insights, Epidemiology and Market Forecast to 2028 |
|
07/30/2019 |
News Article |
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019 |